描述了4-取代的3-氨基-2-氰基噻吩的有效的一锅合成。依次用2.1当量的LDA,1.1当量的O-乙基硫代甲酸酯和1.2当量的2-氯乙腈处理2-烷基或芳基取代的乙腈,以中等至良好的产率得到噻吩。噻吩核心可以很容易地并入更精细的药学相关结构,如仅需两个步骤即可将3-氨基-2-氰基-4-苯基噻吩(1g)转化为各种官能化的噻吩并[3,2- d ]嘧啶类化合物。
描述了4-取代的3-氨基-2-氰基噻吩的有效的一锅合成。依次用2.1当量的LDA,1.1当量的O-乙基硫代甲酸酯和1.2当量的2-氯乙腈处理2-烷基或芳基取代的乙腈,以中等至良好的产率得到噻吩。噻吩核心可以很容易地并入更精细的药学相关结构,如仅需两个步骤即可将3-氨基-2-氰基-4-苯基噻吩(1g)转化为各种官能化的噻吩并[3,2- d ]嘧啶类化合物。
The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents.
The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.